BNIP3L and prostate adenocarcinoma: Homozygous deletions were most prominent in BNIP3L, especially in prostate adenocarcinoma (PRAD), rectal adenocarcinoma (READ) and ovarian serous cystadenocarcinoma (OV) (Figure 7c).